We previously reported the identification of a novel zincfinger gene, designated ZSG, fused to Ewing sarcoma gene (EWS) by a submicroscopic paracentric inversion of 22q12 in a small round cell sarcoma presenting a translocation t(1;22)(p34;q12). We report here the molecular cloning and characterization of the breakpoint in 1p34, which encompasses the gene coding for mitochondrial Hinge protein ubiquinol-cytochrome C reductase hinge gene (UQCRH). All the three breakpoints, two on 22q12 and one in 1p34, interrupt different genes: EWS, ZSG and UQCRH. We determined the genomic structure of UQCRH, characterized its splicing variants and identified a transcribed processed pseudogene. The analysis of UQCRH expression in normal tissues and cancer cell lines revealed absent expression of UQCRH in two ovarian and one breast cancer cell lines and reduced expression in a further breast carcinoma cell line. CpG island methylation upstream exon 1 was detected in all the three cell lines with absent expression. Moreover, treatment with demethylating agent 5-azacytidine restored UQCRH expression in OAW42 ovarian cancer cells. These data provide preliminary evidence of the inactivation of UQCRH gene in cancer either by structural rearrangements or epigenetic mechanisms. Oncogene ( Keywords: EWS; sarcoma; ovarian carcinoma; hinge protein; mitochondrial complex III Sarcomas are a heterogeneous group of malignancies of mesenchymal origin that frequently display nonrandom chromosomal translations creating specific fusion genes. The Ewing family of tumors (EFT) comprises small round cell sarcomas showing moderate neural differentiation that were considered in the past as distinct entities: Ewing's sarcoma, primitive neuroectodermal tumors, peripheral neuroepithelioma and Askin tumor. It is now well documented that almost 95% of EFT share the presence of EWS-FLI1 fusion gene, detected cytogenetically as t(11;22)(q24;q12), or of four other alternative Ewing sarcoma gene (EWS) fusions with different partners (namely ERG, ETV1, FEV. E1AF) (Kovar, 1998). Other sarcoma types display specific fusion genes involving EWS and different partners: CHOP (12q13) in myxoid liposarcoma, WT1 (11p13) in intra-abdominal desmoplastic small round cell tumor, CHN/TEC (9q22) in myxoid chondrosarcoma, ATF1 (12q13) in malignant melanoma of soft parts and ZSG/ PATZ (22q12) in a small round cell sarcoma. In all cases, the identification of the translocation by FISH and/or of the fusion transcript by RT-PCR currently offers an invaluable clue for the correct diagnosis. The exact functions of EWS protein, an RNA-binding protein, are still unclear, but it is widely proven by in vitro studies that the EWS-related fusion genes act as dominant oncogenes with aberrant transcription and possibly splicing features (Arvand and Denny, 2001) .
We previously reported the identification of a novel zincfinger gene, designated ZSG, fused to Ewing sarcoma gene (EWS) by a submicroscopic paracentric inversion of 22q12 in a small round cell sarcoma presenting a translocation t(1;22)(p34;q12). We report here the molecular cloning and characterization of the breakpoint in 1p34, which encompasses the gene coding for mitochondrial Hinge protein ubiquinol-cytochrome C reductase hinge gene (UQCRH). All the three breakpoints, two on 22q12 and one in 1p34, interrupt different genes: EWS, ZSG and UQCRH. We determined the genomic structure of UQCRH, characterized its splicing variants and identified a transcribed processed pseudogene. The analysis of UQCRH expression in normal tissues and cancer cell lines revealed absent expression of UQCRH in two ovarian and one breast cancer cell lines and reduced expression in a further breast carcinoma cell line. CpG island methylation upstream exon 1 was detected in all the three cell lines with absent expression. Moreover, treatment with demethylating agent 5-azacytidine restored UQCRH expression in OAW42 ovarian cancer cells. These data provide preliminary evidence of the inactivation of UQCRH gene in cancer either by structural rearrangements or epigenetic mechanisms. Oncogene (2003 Oncogene ( ) 22, 4586-4593. doi:10.1038 Keywords: EWS; sarcoma; ovarian carcinoma; hinge protein; mitochondrial complex III Sarcomas are a heterogeneous group of malignancies of mesenchymal origin that frequently display nonrandom chromosomal translations creating specific fusion genes. The Ewing family of tumors (EFT) comprises small round cell sarcomas showing moderate neural differentiation that were considered in the past as distinct entities: Ewing's sarcoma, primitive neuroectodermal tumors, peripheral neuroepithelioma and Askin tumor. It is now well documented that almost 95% of EFT share the presence of EWS-FLI1 fusion gene, detected cytogenetically as t(11;22)(q24;q12), or of four other alternative Ewing sarcoma gene (EWS) fusions with different partners (namely ERG, ETV1, FEV. E1AF) (Kovar, 1998) . Other sarcoma types display specific fusion genes involving EWS and different partners: CHOP (12q13) in myxoid liposarcoma, WT1 (11p13) in intra-abdominal desmoplastic small round cell tumor, CHN/TEC (9q22) in myxoid chondrosarcoma, ATF1 (12q13) in malignant melanoma of soft parts and ZSG/ PATZ (22q12) in a small round cell sarcoma. In all cases, the identification of the translocation by FISH and/or of the fusion transcript by RT-PCR currently offers an invaluable clue for the correct diagnosis. The exact functions of EWS protein, an RNA-binding protein, are still unclear, but it is widely proven by in vitro studies that the EWS-related fusion genes act as dominant oncogenes with aberrant transcription and possibly splicing features (Arvand and Denny, 2001) .
We previously reported the identification of a novel fusion gene between EWS and the novel putative transcription factor ZSG, generated by an intrachromosomal rearrangement of chromosome 22, an inversion of 22q12, in a small round cell sarcoma case (Mastrangelo et al., 2000) . We have now completed the characterization of the t(1;22) associated with the 22q12 inversion in the same tumor, and report here that the 1p breakpoint interrupts UQCRH gene and creates fusion genes with both EWS on der(22) and ZSG on der(1). Furthermore, we analysed UQCRH status in a panel of cancer cell lines and provide evidence for its inactivation by epigenetic mechanisms.
Southern blot analysis of ZSG gene on the DNA from a sarcoma tumor sample carrying a translocation t(1;22)(p34;q12) displayed the presence of two rearranged restriction fragments, one of which was generated by the fusion between EWS and ZSG genes (Mastrangelo et al., 2000) . The second rearranged fragment did not contain EWS sequences, as demonstrated by Southern blotting, and attempts to identify the reciprocal product of the 5 0 EWS-ZSG3 0 fusion both at the RNA and at the genomic level failed, suggesting the possibility that this restriction fragment represented a second rearrangement of the ZSG gene. In order to clone this second rearranged fragment, we applied a PCR-based approach Panhandle Variant PCR, a technique that allows highly specific PCR amplification of unknown DNA regions flanking a known sequence, even from complex templates such as human genomic DNA (Jones and Winistorfer, 1997; Megonigal et al., 1998) . Hybridization of PCR products from tumor DNA with an appropriate probe of ZSG exon 1 revealed the wild-type amplification product and an aberrant fragment of 5.4 kb (as expected based on Southern blot data) (Figure 1a ). This fragment was cloned and sequenced, and an unknown sequence was identified Figure 1 (a) Cloning of 5 0 ZSG-UQCRH3 0 from derivative chromosome 1. Panhandle Variant PCR products were amplified as described (Jones and Winistorfer, 1997) . Briefly, ligation of an appropriate oligonucleotide to a restriction endonuclease cut site in the unknown flanking DNA creates an inverted repeat that allows intrastrand annealing and subsequent template-directed extension from the known specific sequence. Patient normal (blood-derived) and tumor-derived genomic DNA was BamHI digested, ligated to primer P3ZSG (5 0 -GCAGCCTTGGCAGC-CAACAGCAATGGCATCGCCG-3 0 in ZSG exon 1, corresponding to bases 1207-1240 in ZSG sequence AF254085) via a bridging oligo (5 0 -GATCCGGCGATGCCATTGC-3 0 ) and amplified with primer PIZSG (5 0 -CTTCCCTTTGGACATGACCAACGGGGCAGCC-3 0 , bases 1182-1212 in ZSG sequence AF254085) using the Extensor Long PCR System (Abgene) and following the manufacturer's instructions. One-fifth of PCR products were loaded in a 1% agarose gel, transferred to nylon membrane and hybridized with a probe containing ZSG exon 1. Templates for PCR were as follows: lanes 1 and 3, digested but not ligated genomic DNA from patient normal and tumor samples, respectively; lanes 2 and 4, digested and ligated genomic DNA from patient normal and tumor samples, respectively; lane 5, negative control with no DNA. Tumor DNA shows the presence of an aberrant fragment and was therefore added of 3 0 A-overhangs, gel-purified, cloned into pGEM-T Easy Vector System (Promega) and sequenced using an ABI PRISM 377 DNA Sequencer (Applied Biosystems). 0 UQCRH-EWS3 0 from derivative chromosome 22. Lanes correspond to PCR product from control normal genomic DNA (C), patient normal genomic DNA (N), patient tumor genomic DNA (T, showing the aberrant 1.9 kb product) and negative control. Primers used are UQCRHintF (5 0 -CATAGGAAACAGAAGTAGAACAAGTGC-3 0 in intron 3) and EWS9R (5 0 -CCAGGCTTATTGAAGCCACCTC-3 0 ); annealing temperature 611C; 40 cycles. PCR product was cloned and sequenced as described. (e) Upper panel: Amplification of 5 0 UQCRH-EWS3 0 from tumor-derived cDNA (T) but not from control muscle cDNA (C). Primers used are UQCRH5F (5 0 -CTTACAAGTCCTTCTTGATCCTGAAC-3 0 ) and EWS11R (5 0 -CTGTTGTCAGAGTCTTCATCTGGATCTAC-3 0 ), 601C, 35 cycles; the 574 bp amplified fragment contains the additional UQCRH exon 2bis located upstream exon 3, as depicted in Figure 3a , and EWS exon 9 (-CAG). The 429 bp fragment represents the fusion between UQCRH exon 3 and EWS exon 9. Lower panel: UQCRH wild-type transcript amplified from both control muscle cDNA and. to a decreased level, tumor cDNA. By cloning and sequencing 10 molecules of the PCR product from tumor cDNA, we observed that they either contain the G allele in exon 2, leading to Glu20Gly nonconservative substitution, or skip the 27 bp of exon 2. Primers used are UQCRH5F and UQCRH5R3 (5 0 -ATGAAGACTGGGGTGAATTAAGTCC-3 0 ); 601C, 35 cycles. (f) Sequence of 5 0 UQCRH-EWS3 0 fusion transcript containing the alternative exon 2bis and UQCRH wild-type transcripts, corresponding to the products amplified from tumor cDNA and described in (e) Inactivation of UQCRH gene P Modena et al that interrupts ZSG exon 1. Sequence similarity searches showed 100% identity with sequence AL122001 from PAC dJ603I14 assigned to 1p32-34. Sanger Centre provided us with this PAC clone, and we refined its localization on 1p34.1 by double-color FISH on normal metaphase spreads using reference probes located in specific chromosomal bands (not shown). We analysed sequence AL122001 using the NIX program (http:// www.hgmp.mrc.ac.uk/Bioinformatics/) and found evidence that the breakpoint is located in intron 3 of the UQCRH gene. We confirmed the presence of the 5 0 ZSG-UQCRH3 0 fusion gene in the primary tumor sample by direct amplification and sequencing of the fusion boundaries from genomic DNA and cDNA (Figure 1b and c). We searched for the reciprocal rearrangement of the newly identified translocation. which could be represented either by 5 0 UQCRH-ZSG3 0 fusion or by 5 0 UQCRH-EWS3 0 , depending on whether the chromosome 22 homolog involved in the translocation was the same as that involved in the inversion or not. We found the presence of 5 0 UQCRH-EWS3 0 fusion in tumor cDNA and genomic DNA (Figure 1d-f) , providing evidence for a translocation associated with the chromosomal inversion on 22q12 (as schematically represented in Figure 2a) . By cloning and sequencing all the genomic breakpoints, we were able to observe that they are associated with a 17 bp deletion in EWS intron 8, a 16 bp duplication in UQCRH intron 3, and a 319 bp duplication in ZSG exon 1 (Figure 2b ). The fusion gene 5 0 EWS-ZSG3 0 gives rise to in-frame transcripts, as described elsewhere (Mastrangelo et al., 2000) ; in contrast, 5 0 ZSG-UQCRH3 0 and 5 0 UQCRH-EWS3 0 fusion genes produce out-of-frame transcripts containing premature stop codons.
We deduced and confirmed the genomic structure of UQCRH gene by sequencing both RT-PCR amplification products and PAC 603I14 using primers from exons ( Figure 3a) . The gene consists of four exons, the promoter region being contained in a 1.9 kb CpG island, and encodes for a mitochondrial protein of 91 amino acids essential for complex formation between cytochrome c1 and cytochrome c (Kim and King, 1983; Mukai et al., 1985; Ohta et al., 1987) . The transcript is approximately 1 kb in length and it is expressed in all tissues analysed, predominantly in tissues with highenergy metabolism and, in particular, in heart and muscle ( Figure 3b ). We performed 3 0 -RACE experiments (not shown) on normal brain and lung total RNA (Clontech) and identified, in addition to the already described wild-type transcript, a low abundance isoform containing an additional exon of 148 bp between exons 2 and 3 (that we named exon 2bis). This sequence is also present in a few human UQCRH ESTs sequences. This second transcript has two putative open reading frames Figure 1a ; sequences from der(22) were obtained by direct amplification from tumor genomic DNA using primers encompassing the cDNA fusion boundaries identified (Mastrangelo et al., 2000 and Figure 1e ). The breakpoints are located in EWS intron 8, ZSG exon 1 and UQCRH intron 3. The small deletions and duplications detected are shaded Inactivation of UQCRH gene P Modena et al (orfs): a 108 amino acids orf retaining the leader sequence and the poly(Glu) stretch, but the C-terminal 72 amino acids have no similarity with known domains; alternatively, a second orf of 85 amino acids is present that would skip the first methionine, the leader sequence and the poly(Glu) stretch, but would maintain the remaining amino-acid sequence of UQCRH plus 21 Nterminal amino acids. RT-PCR amplification of this isoform using a specific forward primer shows that it is expressed at low abundance in most of the tissues tested ( Figure 3c ). This additional exon is efficiently inserted in 5 0 UQCRH-EWS3 0 fusion transcript of our index case (Figure 1e and f) .
By means of sequence similarity searches against the draft human genome sequence, five putative processed pseudogenes could be retrieved. In particular, a processed pseudogene is present in sequence AC058783 assigned to 1p36 by UCSC (http://genome.ucsc.edu/), which still contains the orf of UQCRH gene (with two missense variations), but different 5 0 UTR. RT-PCR on DNase-treated RNA from normal samples using primers that discriminate between gene and putative pseudogene shows ubiquitous expression of UQCRH gene and also expression of the putative pseudogene in some of the tissues tested (Figure 3c ). Subsequent sequencing of RT-PCR products confirms the presence of the missense variations in the expressed pseudogene product.
We analysed the status of UQCRH unrearranged allele in the tumor sample under study, to test whether it was completely inactivated or not. By means of microsatellite loss of heterozygosity (LOH) analysis, we could not detect LOH (data not shown). Exon amplification and sequencing of UQCRH gene in the tumor under study demonstrated the presence of G/A transversion in exon 2, leading to a nonconservative substitution Glu20Gly in the poly(Glu) stretch of Hinge protein. This substitution is constitutional because it is also present in the peripheral blood DNA of the patient. By means of PCR-RFLP, we analysed the genomic DNA from 56 control healthy donors and in 21% of the individuals we identified this substitution, which is therefore a single nucleotide polymorphism. By cloning and sequencing of wild-type UQCRH RT-PCR product from tumor cDNA, we observed that it either contains the G allele or completely skips exon 2 (Figure 1f ). Although we never observed skipping of exon 2 in normal tissue samples and therefore this event might Since the 1p34 region suffers frequent LOH in a variety of human cancers, we analysed the expression of UQCRH gene in a panel of cancer cell lines by Northern blotting. Two (OAW42 and SKOV3) out of eight ovarian carcinoma and one (MDA361) out of nine breast carcinoma cell lines showed complete loss of expression, while one additional breast carcinoma cell line (MDA231) showed highly reduced UQCRH expression; the four neuroblastoma cell lines tested retained mRNA expression (Figure 4a ). Cell lines with loss of expression did not show any alteration at the genomic DNA level as assayed by FISH, Southern blot, and exon amplification and sequencing (not shown). Since UQCRH is located in 1p34 proximal to the MYCL1 gene, a region where the 1p breakpoints associated with MYCN-amplified neuroblastomas are located, and furthermore neuroblastomas and Ewing's family of tumors (to which the case under study belonged) share a common origin from embryonic neural crest cells and may have similar histologic features, we also analysed the UQCRH status on three MYCN-amplified (KCNR, SJNB8, IMR32) cell lines and one MYCN single-copy (SJNB12) neuroblastoma cell line containing 1p34 breakpoints, by a FISH approach using PAC dJ1603I14 as a probe. These experiments showed that UQCRH did not encompass the translocation-associated breakpoints (not shown).
We observed that expression of the UQCRH transcript is restored in OAW42 ovarian carcinoma cell line after treatment with 5-azacytidine demethylation agent (Figure 4b ), suggesting that UQCRH expression is switched off by promoter methylation. We mapped methylation at CpG dinucleotides in the region of the CpG island located upstream the UQCRH coding sequence in all the three cell lines that show complete loss of expression, by a DNA methylation assay based on digestion of cell line genomic DNA with MspI/HpaII restriction endonucleases and subsequent PCR amplification (Figure 4c ). Further upstream HpaII sites are not methylated. Characterization of the extent of methylation of UQCRH promoter by bisulfite modification of genomic DNA and PCR amplification and sequencing showed extensive methylation of the CpG dinucleotides immediately upstream UQCRH 5 0 UTR in OAW42, SKOV3 and MDA361 cell lines, while normal immortalized ovarian epithelium (IOSE) was completely unmethylated (Figure 4d ). We retrieved data on UQCRH expression from NCI60 cDNA microarray analysis of gene expression in human cancer cell lines (Scherf et al., 2000) and observed that, in concordance Figure 4 (a) Northern blot hybridization using UQCRH probe (described in Figure 3b ) of total RNA derived from tumor cell lines. Total RNAs were extracted using RNAzo1B (Tel-Test), 20 mg of RNA was loaded onto 1.2% agarose gel containing formaldehyde, transferred to nylon membanes and hybridized according to standard procedures. Cell lines OAW42, SKOV3 and MDA361 show complete loss of expression, and expression in MDA231 is highly reduced. (b) RT-PCR analysis demonstrating restoration of UQCRH expression in OAW42 ovarian carcinoma cell line upon treatment with 5-azacytidine demethylation reagent. OAW42 cell line was grown in MEM medium (Gibco Life Tech.)+10% fetal bovine serum (Biowhittaker) in the absence or presence of 5-azacytidine (Sigma) for 3 days. Medium was replaced every 24 h. After 72 h, cells were collected and RNA extracted. A measure of 1 mg of RNA was retrotranscribed in the presence (RT+) and in the absence (RTÀ) of reverse transcriptase and PCR amplified as described in Figure 3c , except that UQCRH amplification was extended to 40 cycles. (c) DNA methylation analysis in cancer cell lines with absent expression of UQCRH. Genomic DNA was extracted from MDA361, SKOV3, OAW42 and OVCAR3 cell lines using a Q1Aamp DNA Mini Kit (Qiagen) and digested with restriction endonucleases MspI (methylation insensitive) and HpaII (methylation sensitive), two isoschizomers that cut CCGG sites. Enzymes were then inactivated at 651C for 30 min. A measure of 100 ng of undigested (nd) and digested DNA was used for amplification of regions surrounding MspI/HpaII sites located in 1 kb of the CpG island comprising UQCRH exon 1 and upstream sequence. Optimal cycle number for each PCR was determined as that which produced the expected amplification product from undigested DNA and did not yield product from MspI-digested DNA. Methylation of the two MspI/HpaII sites nearest the UQCRH coding sequence is demonstrated in all three cell lines showing loss of UQCRH expression but not in the OVCAR3 cell line that retains normal levels of expression and was used as control. Sites located upstream are at least in part unmethylated since HpaII does cut. As a control of DNA quality, exon 4 of UQCRH was amplified. Primer sequences and PCR conditions are available upon request. The region analysed is depicted: | ¼ CG site; * ¼ CCGG site; the three PCR fragments analysed (A, B and C) are indicated by arrows connected by a dotted line. (d) Representative electropherograms of PCR products obtained from amplification of 296 bp upstream exon 1 of UQCRH from bisulfite-converted genomic DNA of immortalized normal ovarian epithelium IOSE (upper panel) and OAW42 cell line (lower panel). Protection of CpG dinucleotides representing methylation in OAW42, SKOV3 and MDA361 cell lines is evident in all clones analysed, but was not observed in IOSE cells. For comparison, the expected nucleotide sequences corresponding to converted and unmethylated DNA or nonconverted DNA are reported. Bisulfite conversion of genomic DNA was performed based on standard methods; primers and PCR conditions are available upon request with our data, expression in the SKOV3 cell line was completely switched off and was highly downregulated in MDA 231, while OAW42 and MDA341 cell lines were not included in the analysis. Interestingly, two additional ovarian cancer cell lines that we did not test (OVCAR4 and OVCAR5) were highly downregulated. Combining the data, UQCRH appears to be downregulated in a substantial fraction (four out of 10) of ovarian cancer cell lines.
Hinge protein represents subunit 8 of mitochondrial ubiquinol : cytochrome c oxidoreductase complex (complex III of the respiratory chain), and it has long been known from biochemical studies to interact with both cytochrome c 1 and cytochrome c (Kim and King, 1983) , although its exact function is still unclear. Hinge protein is located on the intermembrane surface of the inner membrane, consists of two a helices connected by two disulfide bridges and is highly acidic (Mukai et al., 1985 : Ohta et al., 1987 . The protein lacks the basic mitochondrion targeting residues that characterizes most mitochondrial proteins, and instead contains a highly acidic presequence. The crystal structure of complex III has been resolved (Iwata et al., 1998) , providing further evidence that the peculiar feature of nine consecutive glutamic residues at the N-terminal of the Hinge protein may be the site of interaction with the basic protein cytochrome c. The protein is highly conserved from yeast to humans. In yeast, the 17 kDa subunit of complex III is the homolog of Hinge protein and deletion mutants are still capable of growth on a nonfermentable substrate, therefore implying that it is not essential for the assembly and function of complex III (Crivellone et al., 1988; Schoppink et al., 1988) . Nonetheless, there is evidence that it may exert a regulatory role of complex III and of its association with cytochrome c (Kim et al., 1989; Schoppink et al., 1989) . Liu and Bradner (1993) reported upregulation of hinge transcript in a prostate cancer cell line, but the authors actually based subsequent studies on the sequence of the 1p36 transcribed pseudogene, since the genomic sequence they studied and deposited (gi385936) is identical to AC058783 and not to AL122001. Okazaki et al. (1998) reported that stable overexpression of Hinge protein into a murine promyeloid cell line accelerates apoptosis induced by stressful conditions. Instead, in a different experimental system of cell toxicity, Santiard-Baron et al. (1999) reported repression of UQCRH transcript in human preneuron NT2 cells upon treatment with neurotoxic b-amyloid peptide. Although a role for UQCRH in mitochondrial-mediated apoptosis is intriguing because of its function and subcellular location, more focused experiments are mandatory to demonstrate UQCRH involvement in proliferation and cell death. Alternatively, UQCRH gene dysfunction might influence tumorigenesis by affecting the superoxide-scavenging activity of the respiratory chain, resembling the hypothesized role of housekeeping genes encoding related mitochondrial proteins, such as succinate dehydrogenases and fumarate hydratase, which act as tumor suppressors in hereditary paragangliomas and uterine fibroids, respectively (Baysal et al., 2000; Rustin, 2002; Tomlinson et al., 2002) .
In conclusion, our data provide preliminary evidence that downregulation of UQCRH gene by either genetic or epigenetic mechanisms is involved in tumorigenesis.
